Entero Therapeutics (Nasdaq:ENTO) - Prezzo delle azioni, notizie e analisi

ENTO Panoramica delle azioni

ENTO analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Gli utili sono cresciuti del 16.2% all'anno negli ultimi 5 anni

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

Ha meno di 1 anno di pista di cassa

Non ha una capitalizzazione di mercato significativa ( $2M )

+ 2 più rischi

Entero Therapeutics, Inc. Concorrenti

Sonnet BioTherapeutics Holdings

NasdaqCM:SONN

US$2.3m

GRI Bio

NasdaqCM:GRI

US$2.1m

Scorpius Holdings

NYSEAM:SCPX

US$2.8m

Salarius Pharmaceuticals

NasdaqCM:SLRX

US$2.2m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Entero Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.45
Massimo di 52 settimane	US$14.51
Minimo di 52 settimane	US$0.18
Beta	1.22
1Variazione di 1 mese	-21.49%
Variazione a 3 mesi	8.98%
Variazione di 1 anno	-90.53%
3Variazione a 3 anni	-99.99%
Variazione a 5 anni	-100.00%
Variazione dall'IPO	-100.00%

Notizie e aggiornamenti recenti

Recent updates

First Wave BioPharma announces pricing of $6.0 million public offering

Oct 07

First Wave BioPharma extends selloff after announcing strategic shift

Sep 19

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

Sep 07

First Wave BioPharma announces 1-for-30 reverse stock split

Aug 25

First Wave BioPharma to raise capital in convertible preferred stocks offering

Jul 15

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

Oct 19

Rendimenti per gli azionisti

	ENTO	US Biotechs	US Mercato
7D	13.3%	4.3%	1.6%
1Y	-90.5%	18.8%	32.3%

Ritorno vs Industria: ENTO ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 18.8 % nell'ultimo anno.

Rendimento vs Mercato: ENTO ha avuto una performance inferiore al mercato US che ha registrato un rendimento 32.3 % nell'ultimo anno.

Volatilità dei prezzi

Is ENTO's price volatile compared to industry and market?
ENTO volatility
ENTO Average Weekly Movement	27.7%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di ENTO è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 28% ) di ENTO è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2014	9	James Sapirstein	www.enterothera.com

Entero Therapeutics, Inc. è una società biofarmaceutica in fase clinica, impegnata nello sviluppo di terapie mirate e somministrate per via orale per il trattamento di pazienti affetti da malattie gastrointestinali. I candidati in pipeline dell'azienda includono la latiglutenasi, un bioterapico orale mirato per la celiachia progettato per scomporre il glutine in peptidi non immunogenici, attualmente in fase di studio di Fase 2, e il capeserod, un agonista parziale selettivo del recettore 5-HT4 in fase di studio di Fase 1 per il trattamento della gastroparesi. È inoltre impegnata nello sviluppo di adrulipasi, un enzima lipasi ricombinante progettato per consentire la digestione dei grassi e di altri nutrienti, attualmente in fase 2 di studio per il trattamento dell'insufficienza pancreatica esocrina in pazienti con fibrosi cistica e pancreatite cronica; e la niclosamide, una piccola molecola orale con terapia inibitoria antinfiammatoria, attualmente in fase 2 di studio per il trattamento della proctite ulcerosa e della proctosigmoidite ulcerosa, nonché della colite e della diarrea associate agli inibitori del checkpoint immunitario nei pazienti affetti da cancro metastatico.

Entero Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Entero Therapeutics con la sua capitalizzazione di mercato?
ENTO statistiche fondamentali
Capitalizzazione di mercato	US$2.21m
Guadagni(TTM)	-US$8.15m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-0.3x

Rapporto P/E

ENTO è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ENTO Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$8.15m
Guadagni	-US$8.15m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.71
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato ENTO nel lungo periodo?

Vedi performance storica e confronto

ENTO Panoramica delle azioni

Premi

Analisi del rischio

Entero Therapeutics, Inc. Concorrenti

NasdaqCM:SONN

US$2.3m

NasdaqCM:GRI

US$2.1m

NYSEAM:SCPX

US$2.8m

NasdaqCM:SLRX

US$2.2m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Less than half of directors are independent

Journey Therapeutics, Inc. entered into a binding term sheet to acquire Entero Therapeutics, Inc. (NasdaqCM:ENTO) in a reverse merger transaction.

Entero Therapeutics Receives Non-Compliance Notice Regarding Nasdaq Listing Rule 5550(a)(2)

Entero Therapeutics Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics, Inc. announced delayed 10-Q filing

Entero Therapeutics Notifies the Nasdaq Stock Market of its Non-Compliance with Nasdaq Rule 5605(c)(2)

Recent updates

Less than half of directors are independent

Journey Therapeutics, Inc. entered into a binding term sheet to acquire Entero Therapeutics, Inc. (NasdaqCM:ENTO) in a reverse merger transaction.

Entero Therapeutics Receives Non-Compliance Notice Regarding Nasdaq Listing Rule 5550(a)(2)

Entero Therapeutics Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics, Inc. announced delayed 10-Q filing

Entero Therapeutics Notifies the Nasdaq Stock Market of its Non-Compliance with Nasdaq Rule 5605(c)(2)

First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $0.9882 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximately $3 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximator $3 million.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $4.000006 million.

First Wave BioPharma, Inc. has withdrawn its Follow-on Equity Offering.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) signed a non-binding term sheet to acquire ImmunogenX, LLC.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering.

First Wave Biopharma, Inc. Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

First Wave BioPharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

First Wave BioPharma Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Listing Rule 5550(b)(1)

First Wave BioPharma, Inc. Announces Initial Topline Results from Phase 2 Span Clinical Trial Investigating Enhanced Adrulipase Formulation

New major risk - Share price stability

First Wave Biopharma Completes Patient Screening for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis

First Wave BioPharma Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis

First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

First Wave BioPharma, Inc. Announces Expansion of Adrulipase Intellectual Property Portfolio

First Wave BioPharma, Inc. Provides Update on IND Filing for Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency

First Wave BioPharma Receives A Deficiency Notice from the Listing Qualifications Staff of Nasdaq Regarding Minimum Bid Price

First Wave BioPharma, Inc. Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma, Inc. Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360

First Wave BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

First Wave BioPharma announces pricing of $6.0 million public offering

First Wave BioPharma, Inc. Provides Update on Clinical Programs

First Wave BioPharma extends selloff after announcing strategic shift

First Wave BioPharma, Inc. Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

First Wave BioPharma Announces Reverse Stock Split

First Wave BioPharma announces 1-for-30 reverse stock split

Price target decreased to US$9.00

High number of new and inexperienced directors

First Wave BioPharma, Inc., Annual General Meeting, Aug 25, 2022

First Wave BioPharma to raise capital in convertible preferred stocks offering

First Wave Biopharma, Inc Announces Resignation from the Board of Directors

First Wave BioPharma, Inc. announced delayed 10-Q filing

First Wave BioPharma, Inc. Appoints David Hoffman as Member of the Board

Price target decreased to US$20.00

High number of new and inexperienced directors

James Pennington Announces His Intention to Retire as Chief Medical Officer of First Wave BioPharma, Inc

First Wave BioPharma, Inc. Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19

First Wave Biopharma, Inc. Announce Chief Financial Officer Changes

First Wave BioPharma, Inc. Provides Update on Adrulipase (FW-EPI) Clinical Program

First Wave BioPharma, Inc. Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections

High number of new directors

First Wave BioPharma Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

Price target decreased to US$25.00

AzurRx BioPharma, Inc. (NasdaqCM:AZRX) agreed to acquire First Wave Bio, Inc. for $230 million.

AzurRx BioPharma, Inc. Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis